The mother and daughter received identical diagnoses just over a year apart of multiple myeloma, a blood cancer that occurs ...

An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...

Many of these advances are the result of decades of work and clinical trials. Since the mid-1990s, the American Cancer ...

Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...

A mother of two, who once feared she would not live to see her children grow up after a persistent sore throat led to an ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...

The five-year survival rate for all cancers combined in the US reached a landmark 70% for Americans diagnosed between 2015 ...